Stock AKBA AKEBIA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Market Closed - Nasdaq
Other stock markets
 02:00:00 04/05/2024 am IST 		5-day change 1st Jan Change
1.37 USD +5.38% Intraday chart for Akebia Therapeutics, Inc. +2.24% +10.48%
23/04 Averoa Seeks EU Approval for Chronic Kidney Disease Drug MT
16/04 Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
PR
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Averoa Seeks EU Approval for Chronic Kidney Disease Drug
MT
Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement
CI
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Sector Update: Health Care Stocks Advance Premarket Thursday
MT
Sector Update: Health Care
MT
Transcript : Akebia Therapeutics, Inc. - Special Call
Akebia Therapeutics Shares Jump Pre-Bell on FDA Approval of Anemia Treatment for Chronic Kidney Disease Dialysis Patients
MT
Akebia Shares Rally Premarket After FDA Approves Vafseo
DJ
U.S. FDA approves Akebia's anemia drug
RE
U.S. FDA approves Akebia's anemia drug
RE
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
PR
Akebia Therapeutics, Inc. Receives FDA Approval of Vafseo Tablets for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
CI
Akebia Therapeutics, Inc. Announces Management Changes, Effective March 22, 2024
CI
Akebia Therapeutics, Inc. Announces Executive Changes, Effective March 22, 2024
CI
Akebia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q4 Revenue $56.2M, vs. Street Est of $55.4M
MT
Akebia Therapeutics, Inc. Provides Revenue Guidance for the Year 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AKBA Stock
  4. News Akebia Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW